SHANGHAI--(BUSINESS WIRE)--With the launch of China’s 12th Five-year Plan for the biomedical industry, China’s antibody drugs development will usher in a golden era. According to prediction of askci.com, by 2015, China’s antibody drugs industry will record a total revenue of over RMB 40 billion, among which monoclonal antibody drugs will contribute over RMB 18 billion.
